SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion.

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jim Bishop who started this subject4/3/2002 10:09:52 AM
From: Dave Gore  Read Replies (2) of 150070
 
HQNT (.69)- up 25% today ---- remember this one- used to be $5.00. Recent big contract, getting noticed. I would DD it. Money flow has been excellent last 3 days. News today as well, but the news a few days ago is what got it moving. $5M net.

H-Quotient, Inc., Announces LabQuotient; $5 Million Net Projected
VIENNA, Va., Mar 25, 2002 /PRNewswire-FirstCall via COMTEX/ -- H-Quotient, Inc., (OTC Bulletin Board: HQNT chart, msgs) and Dr. Thomas C. Laipply, MD, FCAP, FIAP, Director of Molecular Tissue Pathology, Nichols Institute at Quest Diagnostics announced LabQuotient, a relational database for improving and monitoring medical test ordering. The product is expected to be ready for market this summer.

Pre-production orders have been received. Further details will be announced in a subsequent release.

H-Quotient, Inc., is projected to earn net income of $5 million in the product's first year. All income will be recurring and is expected to grow substantially because the universe for this revolutionary product includes clinical doctors, dentists, veterinarians, emergency rooms, urgent care centers, insurance companies, HMOs, hospital quality assurance personnel, commercial laboratories, and pharmaceutical-drug companies.

Dr. Laipply said, "LabQuotient is a new and innovative software product that will significantly improve medical diagnosis and treatment while reducing the ongoing problem of inappropriate and unnecessary testing. It fills the diagnosis/testing gap that has dramatically widened over the last decade."

H-Quotient Vice President of Operations Laurance T. Burden said, "LabQuotient fills a critical need and we are uniquely positioned to deliver it with our advanced technology."

CEO and President Douglas A. Cohn said, "This is quite simply the most significant event in H-Quotient's history, but more important, it will soon have a positive impact on patient care and medical costs."

This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated.

For more information visit the H-Quotient web site at hquotient.com .
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext